Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
By
Jessica Wright
26 February 2019 | 6 min read
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
By
Jessica Wright
24 May 2016 | 6 min read
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
By
Nicholette Zeliadt
17 February 2015 | 5 min read
Explore more from The Transmitter
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
Autism scientists push back on CDC’s inaccurate vaccine claims
The CDC website now falsely suggests that autism-vaccine research is still an open question, prompting distrust among researchers—some of whom anticipate “more unreliable statements coming from the junta that took over” the agency.
By
The Transmitter
21 November 2025 | 6 min read
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
Gene replacement therapy normalizes some traits in SYNGAP1 model mice
The first published virus-based gene therapy for SYNGAP1 deletion yields benefits despite the gene’s long length and complexity.
By
Charles Q. Choi
20 November 2025 | 5 min read
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
Does AI understand what it produces? Henk de Regt explores how we might assess understanding in machines and humans
Building on his philosophy of how scientists understand what they work on, de Regt is extending his approach to test understanding in machines.
By
Paul Middlebrooks
19 November 2025 | 1 min read